



Ocera Therapeutics, Inc.  
Investor Relations Department  
5001 S. Miami Boulevard,  
Suite 300  
Durham, NC 27703  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

#### NASDAQ: OCRX

|               |                            |
|---------------|----------------------------|
| Last Trade:   | 0.96                       |
| Trade Time:   | 4:00 PM ET<br>Sep 19, 2017 |
| Change:       | 0.00 (0.000%)              |
| Day Range     | 0.96 - 1.00                |
| 52-Week Range | 0.52 - 3.15                |
| Volume        | 64,414                     |


Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

[Ocera Therapeutics](#)  
(NASDAQ:OCRX) is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with serious diseases in areas of high unmet medical need.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Aug 23, 2017*

[Ocera Therapeutics Selected to Present an Oral Presentation and Three Posters on OCR-002 at the AASLD Liver Meeting@ 2017](#)

*Aug 1, 2017*

[Ocera Therapeutics Reports Second Quarter 2017 Financial Results](#)

*Jun 1, 2017*

[Ocera Initiates Phase 2a Study with Oral OCR-002 in Patients with Cirrhosis](#)

*May 26, 2017*

[Ocera Therapeutics to Host KOL Conference Call on Hepatic Encephalopathy and Other Complications of Liver Disease on Friday, June 2](#)

*May 9, 2017*

[Ocera Therapeutics Reports First Quarter 2017 Financial Results and Provides Clinical Update](#)

## Financials [\[ View all \]](#)

[First Quarter Financial Results](#)

*Mar 14, 2017*

[Annual Report \(10-K\)](#)

*Apr 25, 2017*

[Proxy Statement \(DEF 14A\)](#)

*Aug 1, 2017*

[Quarterly Report \(10-Q\)](#)

*May 9, 2017*

[Quarterly Report \(10-Q\)](#)

*Nov 2, 2016*

[Quarterly Report \(10-Q\)](#)